Purpose: Diabetes care, particularly type 2 diabetes (T2D), is recognised as a growing challenge in emergency situations. During the humanitarian crisis of war in Ukraine, it is important to focus on ensuring that patients have access to essential medicines for T2D. Since 1 April 2017, the Ministry of Health of Ukraine has been implementing the government programme "Aordable medicines". e List of reimbursed medicines necessary for the treatment of hypertension, diabetes and bronchial asthma includes 3 glucose lowering medicines (GLMs) - gliclazide, metformin, glibenclamide. From 01 April 2019, electronic prescribing has been implemented as part of the "Aordable Medicines" programme. It is important to investigate changes in the availability and aordability of GLMs for the treatment of T2D during the war and future directions in 2022-2023 in Ukraine.
Methods: Information from the State Register of Medicinal Products of the Ministry of Health of Ukraine from March 2023 and February 2022 (before the start of the war) was the subject of the study. Marketing, analytical, graphical, generalisation analyses were applied. Analysis of the cost of 1 DDD GLM according to the WHO ATC/DDD index and solvency ratio analysis were applied.
Results: is study is based on actual data from before the war in Ukraine and now shows that the aordability and
availability of GLMs during the war in 2022-2023 has not changed dramatically. e 'Aordable Medicines' program
was stably implemented, with €111.9 million allocated in 2023 and within 6 months of 2023. e National Health
Service of Ukraine reimbursed €42.8 million to pharmacies for the Reimbursement List. Most Ukrainian manufacturers and foreign GLMs are very aordable due to the reimbursement system. From October 2023, 23 names of test stripes were included in the Reimbursement list of the "Aordable medicines" programme. However, foreign GLMs of innovative groups are moderately aordable for the working population based on the calculated solvency ratio.